Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
MGTA Price/Volume Stats
| Current price | $0.70 | 52-week high | $2.07 |
| Prev. close | $0.76 | 52-week low | $0.32 |
| Day low | $0.68 | Volume | 376,000 |
| Day high | $0.76 | Avg. volume | 848,835 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $0.75 | Market Cap | 42.44M |
MGTA Stock Price Chart Interactive Chart >
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest MGTA News From Around the Web
Below are the latest news stories about MAGENTA THERAPEUTICS INC that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startupThe former CEO of a biotech that shut down after a patient death in a clinical trial has made his way to a new startup backed by Flagship Pioneering. |
Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient DeathMagenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics Inc and trade on the Nasdaq under the ticker symbol DNTH. Magenta's stockholders will own about 2 |
Magenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementMerger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical dat |
Magenta Therapeutics Adopts Limited Duration Stockholder Rights PlanCAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect t |
The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta TherapeuticsBlue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog. |
MGTA Price Returns
| 1-mo | -94.24% |
| 3-mo | -94.23% |
| 6-mo | -94.49% |
| 1-year | -97.06% |
| 3-year | -99.36% |
| 5-year | -99.64% |
| YTD | -88.92% |
| 2022 | -91.08% |
| 2021 | -43.49% |
| 2020 | -48.28% |
| 2019 | 165.96% |
| 2018 | N/A |
Loading social stream, please wait...